TG TherapeuticsTGTX
About: TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Employees: 338
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
53% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 55
23% more capital invested
Capital invested by funds: $2.36B [Q3] → $2.91B (+$552M) [Q4]
22% more call options, than puts
Call options by funds: $137M | Put options by funds: $113M
7% more funds holding
Funds holding: 303 [Q3] → 325 (+22) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 96
3.01% less ownership
Funds ownership: 65.2% [Q3] → 62.19% (-3.01%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Edward White 22% 1-year accuracy 32 / 148 met price target | 21%upside $55 | Buy Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 6 articles about TGTX published over the past 30 days
